Conclusion
In its current state, neuroimaging is still not able to accurately predict dementia in patients affected by Parkinson's disease. However, new techniques sensitive to tissue microstructure/biochemical alterations that reflect the very earliest stages of cognitive involvement are now becoming available. The most predictive technologies are likely to be sensitive to axonal damage, show specificity for underlying neuropathological substrates, such as ligands that bind to tau and amyloid, and may involve multimodal approaches. They will need to be specifically tested longitudinally in large-scale studies of patients with Parkinson's disease to assess their role in early detection of cognitive involvement and ultimately in predicting Parkinson's dementia. The current move towards large-scale, international collaborative imaging initiatives, especially in combination with other clinical and biological modalities is an essential step towards better-powered, longitudinal imaging studies to provide insights into the biology underlying dementia in Parkinson's disease and ultimately pave the way for therapeutic interventions aimed at slowing the development of dementia in Parkinson's disease.
Funding
R.S.W. is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (201567/Z/16/Z) and has received funding from UCL, the Academy of Medical Sciences and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (BRC302/NS/RW/101410). GR is supported by the Wellcome Trust. J.L. has no funding sources to declare. J.A.C.: The Wellcome Centre for Human Neuroimaging is supported by core funding from the Wellcome (203147/Z/16/Z). H.R.M. is supported by Parkinson's UK, the NIHR UCLH BRC, Wellcome Trust, Guarantors of Brain, the Drake Foundation, Cure Parkinson's Trust, S Koe Research Fellowship, CBD Solutions, the PSP Association and the MRC. A.E.S. is supported by grants from Parkinson's UK, ESRC, NIHR, GE Healthcare (23/5/13 PO2580367614), EU Commission and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.
Abbreviations
DAT = dopamine transporter; DTI = diffusion tensor imaging; FDG = fluorodeoxyglucose; MCI = mild cognitive impairment; PDD = Parkinson's disease dementia; PD-MCI = Parkinson's disease with mild cognitive impairment; PiB = Pittsburgh compound B; SPECT = single photon emission computed tomography
Brain. 2018;141(9):2545-2560. © 2018 Oxford University Press